Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This data demonstrates that the complex involvement of TIPRL/LC3/CD133 in liver cancer aggressiveness can together or individually serve as potential biomarkers for the early detection of liver cancer.
|
31727942 |
2019 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells.
|
23438193 |
2013 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Potential Role of CD133 Expression in the Susceptibility of Human Liver Cancer Stem-Like Cells to TRAIL.
|
28281970 |
2016 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy.
|
26758620 |
2016 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133, a widely known liver cancer stem cell marker, plays critical roles in the maintenance of liver cancer stemness.
|
31197130 |
2019 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biology and clinical implications of CD133(+) liver cancer stem cells.
|
22999864 |
2013 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We observed that Cygb is significantly deregulated in human hepatocellular carcinoma (HCC) tissue and its decrease aggravates the growth of liver cancer stem cells (LCSCs) and increases the subpopulation of CD133(+) LCSCs.
|
30365183 |
2019 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to isolate and characterize a small population of CD133+ cells that existed in the HCC cell line SMMC-7721 by MACS and investigated the possible roles of 8-bromo-7-methoxychrysin (BrMC), a synthetic analogue of chrysin, in inhibiting the properties of CD133+ sphere-forming cells (SFCs) derived from the HCC cell line SMMC-7721, namely liver cancer stem cells (LCSCs).
|
23970349 |
2013 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Down-regulating Bmi-1 may inhibit the biological properties of CD133+ LCSC by blocking NF-κB signaling pathway, which lays a scientific foundation for the clinical treatment of liver cancer.
|
29843222 |
2018 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma.
|
22079466 |
2012 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
|
22025269 |
2012 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133 is a specific surface marker for liver cancer stem cells (LCSCs), which is also considered as an important functional factor for tumorigenesis and overall survival in HCC.
|
26370320 |
2015 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we investigated the role of ELK3 in cancer cell invasion and metastasis in CD133+/CD44+ liver cancer stem cells (LCSCs).
|
27959451 |
2017 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockdown of 14-3-3ζ enhances radiosensitivity and radio-induced apoptosis in CD133(+) liver cancer stem cells.
|
24556826 |
2014 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mir-152 inhibits cell proliferation and colony formation of CD133(+) liver cancer stem cells by targeting KIT.
|
25311946 |
2015 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133 liver cancer cells were injected into mice, and the tissues were processed for histology.
|
31646784 |
2020 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present report we describe the differential DNA methylome of CD133-negative and CD133-expressing liver cancer cells.
|
24898317 |
2014 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The stem cell properties of CD133(+) SFCs were validated by the tumorsphere formation assay in vitro and the xenograft nude mouse model in vivo, and termed liver cancer stem cells (LCSCs).
|
24431896 |
2013 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma.
|
22773665 |
2012 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
|
23233126 |
2013 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133+ liver cancer cells are characterized by resistance to chemotherapy, self-renewal, multilineage potential, increased colony formation, and in vivo cancer initiation at limited dilution.
|
20196115 |
2010 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Also, CXCR3-A suppressed the adhesion ability of CD133+ liver cancer cells that stimulated by CXCL9 for 24h.
|
26883105 |
2016 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Altogether, CD133-induced TM4SF5 expression and function were important for liver cancer sphere growth and may be a promising target to block metastasis.
|
30217560 |
2018 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Systems approach to characterize the metabolism of liver cancer stem cells expressing CD133.
|
28367990 |
2017 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we found that oxidative stress increase CD133 expression in HCC and increased CD133 expression enhanced the capacity of the defense system against ROS, and thereby play a central role in resistance to liver cancer therapy.
|
28253902 |
2017 |